SOAT1 and congenital rubella syndrome: Consistent with this, inhibiting JAK-STAT signaling with baricitinib significantly improved recovery time and survival rates among patients with severe COVID-19, likely by suppressing the CRS (Kalil et al., 2020; Stebbing et al., 2021).